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We examined the association between non-steroidal anti-inflammatory drug (NSAID) use and ovarian cancer by potential effect
modifiers, parity and oral contraceptive use, in a population-based case–control study conducted in Wisconsin and Massachusetts.
Women reported prior use of NSAIDs and information on risk factors in a telephone interview. A total of 487 invasive ovarian
cancer cases and 2653 control women aged 20–74 years were included in the analysis. After adjustment for age, state of residence
and other covariates, ever use of NSAIDs was inversely associated with ovarian cancer in never users of oral contraceptives (odds
ratio (OR)¼0.58, 95% confidence interval (CI) 0.42–0.80) but not for ever users (OR¼0.98, 95% CI 0.71–1.35) (P-
interaction¼0.03). A reduced risk with NSAID use was also noted in nulliparous women (OR¼0.47, 95% CI 0.27–0.82) but not
among parous women (OR¼0.81, 95% CI 0.64–1.04) (P-interaction¼0.05). These results suggest that use of NSAIDs were
beneficial to women at greatest risk for ovarian cancer.
British Journal of Cancer (2008) 98, 1781–1783. doi:10.1038/sj.bjc.6604392 www.bjcancer.com
Published online 27 May 2008
& 2008 Cancer Research UK
Keywords: ovarian cancer; non-steroidal anti-inflammatory drugs; parity; oral contraceptives
                                           
Over the last 10 years, a new hypothesis has emerged, suggesting
that the presence of chronic inflammation might play a causal role
in the development of ovarian cancer (Ness and Cottreau, 1999).
Inflammation might be due to the process of ovulation itself or the
presence of chronic inflammatory agents (Fleming et al, 2006). Non-
steroidal anti-inflammatory drugs (NSAIDs) have been linked to a
lower risk of several cancers (Bosetti et al,2 0 0 6 ) ,a n dN S A I D sc o u l d
in theory have a similar protective influence in ovarian cancer by
mitigating the deleterious effects of inflammation on ovarian
epithelium. Results of several observational studies and one
randomised trial (Cook et al, 2005) of NSAIDs and ovarian cancer
risk are inconsistent. Five small studies detected a modestly
decreased risk, but lacked statistical power (Cramer et al, 1998;
Rosenberg et al, 2000; Akhmedkhanov et al, 2001; Lacey et al, 2004;
Schildkraut et al,2 0 0 6 ) .F i v es t u d i e s( T a v a n iet al,2 0 0 0 ;M o y s i c h
et al, 2001; Fairfield et al,2 0 0 2 ;M e i e ret al, 2002; Friis et al,2 0 0 3 )
plus a meta-analysis (Bonovas et al, 2005) have demonstrated no
association with aspirin or other non-aspirin NSAID use. One study
suggested an increased risk (Sorensen et al,2 0 0 3 ) .L a c ko f
consistent findings in prior studies of NSAID use could reflect
heterogeneity across study populations on factors such as parity and
oral contraceptive use, which may reduce inflammation by
suppressing ovulation. We explored the relationship of NSAID use
with ovarian cancer risk, and whether NSAID associations depended
on potential interactions with oral contraceptive use and parity in a
US population-based case–control study.
MATERIALS AND METHODS
The study has been described in detail in previous reports
(Peterson et al, 2006). Briefly, women aged 20–74 years diagnosed
with incident invasive epithelial ovarian cancer (ICDO-C56)
between 1998 and 2001 from Wisconsin and Massachusetts were
identified through state-wide cancer registries. Controls were
randomly selected in each state using two sampling frames: (1) for
women o65 years, a list of licensed drivers; or (2) for women X65
years, rosters of Medicare beneficiaries compiled by the Centers
for Medicare and Medicaid Services. All eligible controls had a
publicly available telephone number. Controls were frequency-
matched within 5-year stratum to the age distribution of ovarian
and breast cancer cases enrolled in a concurrent study (Sprague
et al, 2007). All study participants provided informed consent to
participate. Response rates were 67% for cases and 82% for
controls.
All eligible women were mailed an introductory study letter
before contact by study personnel. A trained interviewer
conducted a 45-min telephone survey, which elicited information
on use of NSAIDs, including the frequency, start and stop dates,
duration of use, and type. Only episodes of use before a reference
date were included; the reference date was the date of diagnosis for
cases and the date 1 year before interview for controls. Non-
steroidal anti-inflammatory drugs included both aspirin types and
non-aspirin NSAID types (e.g., ibuprofen). ‘Ever use’ was defined
as the use of any NSAID for at least twice per week for 6 months or
more. A woman was defined as a ‘current user’ of NSAIDs if she
reported use within 12 months of the reference date and lasting at
least 6 months in duration. ‘Former use’ was defined as use for at
least 6 months duration, but before the 12 months preceding the
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sreference date. ‘Never use’ was defined as use of NSAIDs for less
than 6 months or less than twice per week. Information on other
risk factors for ovarian cancer, including oral contraceptive use
and parity, were also elicited during the interview. Cases (n¼18)
and controls (n¼562) were excluded if they had missing data on
NSAID use. The final sample included 487 cases and 2653 controls.
Multivariable logistic regression analysis was used to calculate
odds ratios (OR) and 95% confidence intervals (CIs) from Stata 9
(Stata Corp, College Station, TX, USA) (Breslow and Day, 1980).
The main model included terms for age, state of residence, study
year, menopausal status, body mass index, parity, oral contra-
ceptive use, history of tubal ligation, hysterectomy and family
history of ovarian cancer. Tests for trend with two-sided P-values
were evaluated by entering the categorical terms as an ordinal
variable in the model. To test for interaction of NSAIDs with oral
contraceptive use and parity, a cross-product term was entered
Table 1 Demographic characteristics of ovarian cancer cases and
population-based controls
Cases (n¼487) Controls (n¼2653)
Demographic characteristics N (%) N (%)
Mean age (s.d.), years 55 (11.6) 54 (10.1)
High school degree 196 (42.8) 1070 (42.8)
Overweight or obese 272 (55.9) 1374 (51.8)
Oral contraceptive use 220 (45.5) 1411 (53.7)
Mean age (s.d.) at first birth, years 23.9 (4.5) 23.8 (4.5)
Nulliparous 105 (21.6) 311 (11.7)
Postmenopausal 309 (63.4) 1425 (53.7)
Ever smoker 253 (52.0) 1402 (52.8)
Tubal ligation 87 (17.9) 653 (24.6)
Hysterectomy 107 (22.0) 380 (14.3)
Family history of ovarian cancer 24 (4.9) 70 (2.6)
Table 2 Risk of ovarian cancer associated with NSAID use overall and stratified by oral contraceptive use and parity
Cases Controls Cases Controls
NSAID use N (%) N (%) OR (95% CI)
a N (%) N (%) OR (95% CI)
a,b P-interaction
Overall
Never use 336 (70.7) 1711 (65.7) 1.00 (Referent)
Ever use 139 (29.3) 893 (34.3) 0.74 (0.59–0.92)
Former 45 (9.6) 220 (8.6) 0.96 (0.67–1.37)
Current 90 (19.1) 637 (24.8) 0.68 (0.52–0.88)
Aspirin only 64 (16.0) 396 (18.8) 0.73 (0.54–1.00)
Ibuprofen only 59 (14.9) 424 (19.9) 0.68 (0.50–0.93)
Duration (years)
o1 29 (6.1) 189 (7.3) 0.74 (0.49–1.14)
1–4 50 (10.5) 378 (14.5) 0.64 (0.46–0.88)
5–9 30 (6.3) 150 (5.8) 0.94 (0.61–1.44)
X10 30 (6.3) 176 (6.8) 0.78 (0.50–1.19)
P-trend 0.03
Never used oral contraceptives Ever used oral contraceptives
(n¼276) (n¼1483) (n¼222) (n¼1669)
Never use 189 (74.1) 758 (63.7) 1.0 (Referent) 144 (66.4) 935 (67.4) 1.0 (Referent)
Ever use 66 (25.9) 432 (36.3) 0.58 (0.42–0.80) 73 (33.6) 453 (32.6) 0.98 (0.71–1.35) 0.03
Former 18 (7.1) 94 (8.0) 0.69 (0.40–1.20) 27 (12.6) 125 (9.1) 1.32 (0.82–2.12) 0.1
Current 46 (18.2) 321 (27.4) 0.56 (0.39–0.80) 44 (20.5) 309 (22.6) 0.85 (0.58–1.26)
Aspirin only 38 (15.0) 218 (18.4) 0.63 (0.42–0.93) 26 (12.0) 175 (12.7) 0.97 (0.60–1.57) 0.04
Ibuprofen only 20 (7.9) 180 (15.2) 0.45 (0.27–0.75) 39 (18.1) 239 (17.3) 0.95 (0.63–1.43)
Duration (years)
o1 15 (5.9) 89 (7.5) 0.67 (0.37–1.21) 14 (6.5) 98 (7.1) 0.89 (0.48–1.65) 0.04
1–4 20 (7.8) 188 (15.8) 0.42 (0.26–0.69) 30 (13.8) 187 (13.5) 0.96 (0.61–1.49)
5–9 14 (5.5) 76 (6.4) 0.62 (0.33–1.14) 16 (7.4) 72 (5.2) 1.56 (0.86–2.85)
X10 17 (6.7) 79 (6.6) 0.82 (0.46–1.45) 13 (6.0) 96 (6.9) 0.71 (0.36–1.39)
P-trend 0.008 0.85
Nulliparous Parous
(n¼110) (n¼382) (n¼392) (n¼2811)
Never use 79 (78.2) 197 (64.4) 1.0 (Referent) 257 (68.7) 1514 (66.0) 1.0 (Referent)
Ever use 22 (21.8) 109 (35.6) 0.47 (0.27–0.82) 117 (31.3) 781 (34.0) 0.81 (0.64–1.04) 0.05
Former 6 (6.0) 32 (10.6) 0.42 (0.16–1.08) 39 (10.5) 188 (8.3) 1.15 (0.78–1.68) 0.1
Current 15 (15.0) 72 (23.9) 0.48 (0.25–0.94) 75 (20.2) 562 (24.8) 0.72 (0.54–0.96)
Aspirin only 8 (7.9) 40 (13.2) 0.48 (0.20–1.11) 56 (15.1) 355 (15.5) 0.78 (0.57–1.09) 0.3
Ibuprofen only 12 (11.9) 60 (19.8) 0.45 (0.22–0.92) 47 (12.7) 362 (15.8) 0.77 (0.55–1.08)
Duration (years)
o1 7 (6.9) 20 (6.5) 0.80 (0.32–2.03) 22 (5.9) 167 (7.3) 0.75 (0.46–1.20) 0.03
1–4 6 (5.9) 51 (16.7) 0.30 (0.12–0.74) 44 (11.8) 326 (14.2) 0.72 (0.51–1.03)
5–9 4 (4.0) 17 (5.6) 0.54 (0.17–1.74) 26 (7.0) 133 (5.8) 1.06 (0.67–1.67)
X10 5 (5.0) 21 (6.9) 0.47 (0.15–1.48) 25 (6.7) 155 (6.8) 0.88 (0.55–1.39)
P-trend 0.01 0.25
aAdjusted for age, year of interview, state of residence, tubal ligation, family history of ovarian cancer, hysterectomy and menopausal status.
bEach analysis is adjusted for the other
two variables in the table.
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sinto the model, and the likelihood ratio test was used to test the
difference between the full model and reduced model.
RESULTS
Case women were similar to control women with respect to age,
education, age at first birth and smoking status (Table 1). Cases
were more likely than control women to have not used oral
contraceptives, be nulliparous or postmenopausal, or have had a
tubal ligation or a family history of ovarian cancer.
Overall, we observed a reduction in risk among women who had
ever used any type of NSAID compared to non-users (OR¼0.74,
95% CI 0.59–0.92) (Table 2). When considered according to oral
contraceptive use, ever use of NSAIDs was inversely associated
with ovarian cancer in never users (OR¼0.58, 95% CI¼0.42–
0.80), but there was no association among ever users (OR¼0.98,
95% CI¼0.71–1.35) of these medications (P-interaction¼0.03)
(Table 2). The reduction in risk was seen for both current and
former users among never oral contraceptive users. A reduced risk
with NSAID use was limited to nulliparous women (OR¼0.47,
95% CI¼0.27–0.82), whereas there was little evidence of
association among parous women (OR¼0.81, 95% CI¼0.64–
1.04) (P-interaction¼0.05). There was a significant decreasing
trend in risk with increasing years of NSAID use among
nulliparous women alone (P-trend¼0.01).
DISCUSSION
Results from this study indicate an overall 30% reduction of
ovarian cancer associated with ever and current use of NSAIDs.
Further, NSAID users who are nulliparous or have not used oral
contraceptives had the greatest reductions in risk. Both pregnancy
and use of oral contraceptives are associated with decreased
ovarian cancer risk through their inhibitory effects on
ovulation, due to incessant ovulation (Fathalla, 1971). At the site
of ovum release, ovulation is associated with leukocyte
invasion, release of nitric oxide and inflammatory cytokines,
vasodilation, DNA repair, and tissue remodelling (Fleming et al,
2006). The use of NSAIDs could potentially mitigate the
inflammatory effect of ovulation, possibly at the site of ovarian
inclusion cysts.
There are some limitations that should be considered in the
present analysis. We relied on the subject’s ability to recall the use
of NSAIDs, which could have introduced misclassification and
potential bias towards the null. Although there are reports
suggesting that age and education might influence recall, it has
been shown that more frequent use of NSAIDs is more reliably
recalled than less frequent use (Lewis et al, 2006; West et al, 1995).
Therefore, to improve the sensitivity, we attempted to identify true
and consistent users by limiting ever use of NSAIDs to at least two
tablets per week for 6 months or more.
These results suggest that NSAIDs may confer greater protection
from ovarian cancer in women with higher background levels of
inflammation such as those from incessant ovulation.
ACKNOWLEDGEMENTS
This research was funded by National Institute of Health Grants
R01 CA47147 and CA47305. We are indebted to Drs. Linda Titus-
Ernstoff, John Baron, Patrick Remington, Meir Stampfer and
Walter Willett for advice and consultation at various stages
regarding the conduct of this study, and Deanne Young for
editorial assistance.
REFERENCES
Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL,
Shore RE (2001) Aspirin and epithelial ovarian cancer. Prev Med 33:
682–687
Bonovas S, Filioussi K, Sitaras NM (2005) Do nonsteroidal anti-
inflammatory drugs affect the risk of developing ovarian cancer? A
meta-analysis. Br J Clin Pharmacol 60: 194–203
Bosetti C, Gallus S, La Vecchia C (2006) Aspirin and cancer risk: an updated
quantitative review to 2005. Cancer Causes Control 17: 871–888
Breslow NE, Day NE (1980) Statistical methods in cancer research. Volume
I – the analysis of case–control studies. IARC Sci Publ 1(32): 5–338
Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE,
Hennekens CH, Buring JE (2005) Low-dose aspirin in the primary
prevention of cancer: the Women’s Health Study: a randomized
controlled trial. JAMA 294: 47–55
Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg
ER (1998) Over-the-counter analgesics and risk of ovarian cancer. Lancet
351: 104–107
Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE (2002)
Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer
Causes Control 13: 535–542
Fathalla MF (1971) Incessant ovulation – a factor in ovarian neoplasia?
Lancet 2: 163
Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL (2006)
Incessant ovulation, inflammation and epithelial ovarian carcinogenesis:
revisiting old hypotheses. Mol Cell Endocrinol 247: 4–21
Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003)
A population-based cohort study of the risk of colorectal and other
cancers among users of low-dose aspirin. Br J Cancer 88: 684–688
Lacey Jr JV., Sherman ME, Hartge P, Schatzkin A, Schairer C (2004)
Medication use and risk of ovarian carcinoma: a prospective study. Int
J Cancer 108: 281–286
Lewis JD, Strom BL, Kimmel SE, Farrar J, Metz DC, Brensinger C, Nessel L,
Localio AR (2006) Predictors of recall of over-the-counter and
prescription non-steroidal anti-inflammatory drug exposure. Pharmaco-
epidemiol Drug Saf 15: 39–45
Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or
nonsteroidal antiinflammatory drugs and risk of developing ovarian,
breast, or colon cancer. Pharmacotherapy 22: 303–309
Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H (2001)
Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol
Biomarkers Prev 10: 903–906
Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation
in ovarian cancer. J Natl Cancer Inst 91: 1459–1467
Peterson NB, Trentham-Dietz A, Newcomb PA, Chen Z, Gebretsadik T,
Hampton JM, Stampfer MJ, Willett WC, Egan KM (2006) Relation of
anthropometric measurements to ovarian cancer risk in a population-
based case–control study (United States). Cancer Causes Control 17:
459–467
Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, Stolley
PD, Shapiro S (2000) A case–control study of analgesic use and ovarian
cancer. Cancer Epidemiol Biomarkers Prev 9: 933–937
Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck
A (2006) Analgesic drug use and risk of ovarian cancer. Epidemiology 17:
104–107
Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK,
Ekbom A, Baron JA (2003) Risk of cancer in a large cohort of nonaspirin
NSAID users: a population-based study. Br J Cancer 88: 1687–1692
Sprague BL, Trentham-Dietz A, Newcomb PA, Titus-Ernstoff L, Hampton
JM, Egan KM (2007) Lifetime recreational and occupational physical
activity and risk of in situ and invasive breast cancer. Cancer Epidemiol
Biomarkers Prev 16: 236–243
Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S (2000)
Aspirin and ovarian cancer: an Italian case–control study. Ann Oncol 11:
1171–1173
West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A (1995)
Recall accuracy for prescription medications: self-report compared with
database information. Am J Epidemiol 142: 1103–1112
NSAIDs and ovarian cancer
KJ Wernli et al
1783
British Journal of Cancer (2008) 98(11), 1781–1783 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s